GlassScriptPhysician profile
Salim G Contractor
NPI 1033284823
$66,178.47
in general payments reported to CMS, 2019-2025
28 companies · $9,976 in 2025
The $9,976 reported for 2025 was more than what 81% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,213 · 2020: $5,050 · 2021: $16K · 2022: $16K · 2023: $3,072 · 2024: $14K · 2025: $9,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $2,534 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Honoraria: $1,200 · Food and Beverage: $417 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,602.50 |
| Travel and Lodging | $2,533.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Honoraria | $1,200.00 |
| Food and Beverage | $416.61 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24,206.57 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $12,165.89 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $6,275.06 | 2019-2021 | |
| Avyxa Pharma, LLC | $4,101.06 | 2024-2025 | |
| Dova Pharmaceuticals | $3,040.00 | 2021 | |
| Cti Biopharma Corp. | $3,000.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,995.00 | 2021-2022 | |
| Beigene USA, INC. | $1,585.00 | 2020-2024 | Brukinsa |
| Coherus Oncology, INC. | $1,350.00 | 2022 | |
| Tg Therapeutics, INC. | $1,237.50 | 2021 | |
| Blueprint Medicines Corporation | $1,182.00 | 2021 | |
| Celgene Corporation | $1,155.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $950.00 | 2019 | |
| Genentech USA, INC. | $855.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $848.07 | 2020-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $500.00 | 2021 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Sobi, INC | $200.00 | 2024 | |
| Daiichi Sankyo INC. | $200.00 | 2023 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Lilly USA, LLC | $196.64 | 2019-2021 | |
| Astellas Pharma US INC | $194.00 | 2021-2023 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Epizyme, INC. | $99.00 | 2021 | |
| Merck Sharp & Dohme LLC | $62.01 | 2019 | |
| Sirtex Medical INC | $17.82 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salim Contractor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.